Thrombocytopenia, an important interfering factor of antiviral therapy and hepatocellular carcinoma treatment for chronic liver diseases

Kurume Medical Journal

Volumn 56, Issue 1-2, 2009, Pages 9-15

  Kawaguchi, Takumi ^a   Kurumatsu, Ryoko ^a   Ide, Tatsuya ^a   Taniguchi, Eitaro ^a   Itou, Minoru ^a   Sakata, Masahiro ^a   Abe, Mitsuhiko ^a   Sumie, Shuji ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Eltrombopag; Hepatocellular carcinoma; Liver cirrhosis; Peginterferon; Thrombocytopenia

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

AGED; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; BLOOD; LIVER TUMOR; MIDDLE AGED;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PLATELET COUNT; THROMBOCYTOPENIA;

EID: 77950348986     PISSN: 00235679     EISSN: 18812090     Source Type: Journal    
DOI: 10.2739/kurumemedj.56.9     Document Type: Article

References (32)

1. Pohl A, Behling C, Oliver D, Kilani M, Monson P et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001; 96:3142-3146.
2. Poynard T, and Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4:199-208.
3. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007; 132:103-112.
4. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
5. Morita S, Matsumoto S, and Odani R. Hepatic artery infusion chemotherapy with cisplatin and adriamycin in combination with angiotensin-II in the treatment of malignant liver tumors. Gan To Kagaku Ryoho 1988; 15:689-695. (in Japanese)
6. Paquet KJ. Surgery for cirrhotic patients with hepatocellular carcinoma and hypersplenism. Surg Endosc 2001; 15:104-105.
7. Han MJ, Zhao HG, Ren K, Zhao DC, Xu K et al. Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients. Cardiovasc Intervent Radiol 1997; 20:125-127.
8. Hidaka H, Kokubu S, Saigenji K, Isobe Y, and Maeda T. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 2002; 23:265-273.
9. Hirooka M, Ishida K, Kisaka Y, Uehara T, Watanabe Y et al. Efficacy of splenectomy for hypersplenic patients with advanced hepatocellular carcinoma. Hepatol Res 2008; 38:1172-1177.
10. Miyake Y, Ando M, Kaji E, Toyokawa T, Nakatsu M et al. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res 2008; 38:980-986.
11. McCormick PA, and Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:1009-1031.
12. Zekry A, and Freiman J. Eltrombopag: Is this "24 karat gold platelet" treatment for thrombocytopenia in cirrhosis associated with hepatitis C? Hepatology 2008; 47:1418-421.
13. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001; 113:590-595.
14. Rios R, Sangro B, Herrero I, Quiroga J, and Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005; 100:1311-1316.
15. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM et al. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapyassociated severe thrombocytopenia: a randomised crossover study. Lancet 2002; 359:2145-2152.
16. Yamane A, Nakamura T, Suzuki H, Ito M, Ohnishi Y et al. Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes. Blood 2008; 112:542-550.
17. Sata M, Fujita M, Ueno T, Nagata E, and Tanikawa K. Killing two birds with one treatment. J Hepatol 1997; 27:1140.
18. Sata M, Yano Y, Yoshiyama Y, Ide T, Kumashiro R et al. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol 1997; 32:206-210.
19. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109:4607-4616.
20. Sellers T, Hart T, Semanik M, and Murthyl K. Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs. Blood 2004; 104:568a. Abstract 2063.
21. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741.
22. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-2247.
23. McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227-2236.
24. Boukour S, and Cramer EM. Platelet interaction with bacteria. Platelets 2005; 16:215-217.
25. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165:1499-1508.
26. Bonifacio L, Petrova A, Nanjundaswamy S, and Mehta R. Thrombocytopenia related neonatal outcome in preterms. Indian J Pediatr 2007; 74:269-274.
27. Sugimachi K, Ikeda Y, Tomikawa M, Taketomi A, Tsukamoto S et al. Appraisal of hepatic resection in the treatment of hepatocellular carcinoma with severe thrombocytopenia. World J Surg 2008; 32:1077-1081.
28. Shaheen AA, and Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46:912-921.
29. Molina V, and Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005; 38:235-245.
30. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343:1673-1680.
31. Backus LI, Boothroyd DB, Phillips BR, and Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47.
32. El-Serag HB, Marrero JA, Rudolph L, and Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134:1752-1763.